parenteral administration while meeting regulatory expectations.

2. Scope

This SOP applies to all formulation scientists and development teams involved in the design, development, and preliminary evaluation of intravenous injection formulations within the Sterile Injectable Manufacturing department.

3. Responsibilities

• Formulation Scientist: Conducts pre-formulation and formulation trials, documents development work, and prepares trial batches.
• Analytical Team: Performs required testing for solubility, pH, osmolality, and stability studies.
• QA Personnel: Verifies records and reviews development documentation for compliance.
• Department Head: Reviews and approves formulation protocols and reports.

4. Accountability

The Head of Formulation Development is accountable for ensuring compliance with this SOP and for the integrity of the data generated during the formulation development of IV injections.

5. Procedure

5.1 Literature and Regulatory Review

1. Review relevant pharmacopeial standards (e.g., IP, USP, EP) for IV injection requirements.
2. Identify existing formulation benchmarks from innovator products or published studies.

5.2 Pre-Formulation Studies

1. Characterize the active pharmaceutical ingredient (API) for:
   • Solubility in water and buffers
   • pH stability profile
   • Compatibility with excipients
2. Determine the need for solubilizers or co-solvents (e.g., PEG, propylene glycol).

5.3 Formulation Trials

1. Prepare multiple formulation prototypes varying:
   • Buffer composition and pH (targeting 4.0 to 8.0)
   • Isotonicity adjusters (e.g., sodium chloride, dextrose)
   • Preservatives (if multi-dose product)
2. Target osmolality between 270–310 mOsm/kg for isotonicity.
3. Conduct filterability and clarity checks on each prototype.

5.4 Stability Testing

1. Initiate accelerated and long-term stability studies as per ICH guidelines.
2. Monitor for color change, pH shift, precipitation, or microbial growth.
3. Stability data to be recorded in Formulation Stability Log (Annexure-1).

5.5 Sterilization Method Selection

1. Evaluate sterilization options:
   • Autoclaving (moist heat)
   • Sterile filtration (0.22 µm) for heat-labile formulations
2. Document filter compatibility and extractables/leachables study results.

5.6 Documentation and Reporting

1. Prepare a Formulation Development Report (Annexure-2) summarizing:
   • Trial formulation compositions
   • Critical observations
   • Analytical results
   • Rationale for final composition
2. Submit report to QA for review and archival.

6. Abbreviations

• SOP: Standard Operating Procedure
• IV: Intravenous
• API: Active Pharmaceutical Ingredient
• QA: Quality Assurance
• ICH: International Council for Harmonisation

7. Documents

1. Formulation Stability Log – Annexure-1
2. Formulation Development Report – Annexure-2
3. Excipient Compatibility Chart – Annexure-3

8. References

• ICH Q8 – Pharmaceutical Development
• WHO TRS 1025 Annex 2 – GMP for Sterile Products
• USP General Chapter <797> – Sterile Preparations

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Officer	Head – Formulation Development
Department	R&D	Quality Assurance	Formulation Development

11. Annexures

Annexure-1: Formulation Stability Log

Date	Batch No.	Condition	pH	Osmolality	Observation	Tested By
10/06/2025	IV/DEV/001	40°C/75% RH	6.8	295	No change	Rajesh Kumar

Annexure-2: Formulation Development Report

Report No.	FDR/IV/2025/01
API	Paracetamol
Final Composition	Paracetamol 1g, Water for Injection q.s. to 100 mL
Stability Conclusion	Stable up to 6 months (accelerated)
Prepared By	Sunita Reddy

Annexure-3: Excipient Compatibility Chart

Excipient	Purpose	Compatibility with API	Remarks
Sodium Metabisulfite	Antioxidant	Compatible	No degradation observed
PEG 400	Co-solvent	Compatible	Improved solubility

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
10/03/2022	1.0	Initial Release	New SOP	QA Head
18/06/2025	2.0	Added osmolality and sterilization method guidance	Regulatory Update	QA Head